Can Mounjaro Cause Low Blood Pressure? The Cardiovascular Data and When to Worry

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) causes a modest average blood pressure reduction of 4-8 mmHg systolic, which is clinically beneficial for most patients
• In the pooled Zepbound trials, hypotension (including orthostatic hypotension) was reported in 1.6% of tirzepatide patients versus 0.1% on placebo, and in 2.2% of those also taking blood-pressure medication versus 1.2% of those not (Zepbound prescribing information, revised 08/2026); the Mounjaro label lists no hypotension row at all
• Dizziness was reported by 4% to 5% of tirzepatide patients versus 2% on placebo in the Zepbound label's Table 1, and the label notes hypotension often occurred alongside gastrointestinal side effects and dehydration
• The blood pressure effect is dose-dependent: higher tirzepatide doses produce greater reductions, which may require medication adjustments for patients on blood pressure drugs

The short answer

Mounjaro typically lowers blood pressure modestly rather than causing problematic hypotension. Across the SURPASS trials in type 2 diabetes, systolic pressure fell about 5 to 7 mmHg more than on comparators (pooled 4.8, 5.8 and 7.0 mmHg at 5, 10 and 15 mg; Lingvay et al., Cardiovascular Diabetology 2023), and in the SURMOUNT obesity trials the placebo-adjusted drop was 5.6 to 6.7 mmHg at 72 weeks (Zepbound label Table 3). Hypotension was reported in 1.6% of tirzepatide patients versus 0.1% on placebo; it was more common in people also taking blood-pressure medication (2.2% versus 1.2%), though not confined to them.

Table of contents

1. The blood pressure data: what the trials actually show
2. The mechanism: how tirzepatide affects cardiovascular function
3. Orthostatic hypotension vs sustained low blood pressure
4. The three patient profiles: who experiences blood pressure drops
5. What most articles get wrong about GLP-1 medications and blood pressure
6. The medication interaction problem: when to adjust your BP drugs
7. Symptoms that indicate problematic hypotension
8. The FormBlends titration pattern: what we observe in real-world use
9. The decision tree: managing blood pressure changes on tirzepatide
10. When blood pressure reduction is the goal, not a side effect
11. What the labels report
12. How much it lowers blood pressure
13. Does Mounjaro raise blood pressure or heart rate
14. If you take blood pressure medication
15. How quickly it lowers blood pressure
16. FAQ
17. Footer disclaimers

The blood pressure data: what the trials actually show

The published SURPASS trial series (SURPASS-1 through SURPASS-5) enrolled 6,700+ patients on tirzepatide for type 2 diabetes management. Blood pressure was a secondary endpoint tracked across all trials.

Correction, September 2026: the table that used to appear here listed trial-by-trial systolic changes and per-dose hypotension percentages that do not match the published papers. It has been replaced with the figures from the primary sources.

Source	Population	Systolic change versus comparator	Low blood pressure
Lingvay et al., Cardiovascular Diabetology 2023 (SURPASS-1 to -5, 40 to 42 weeks)	Type 2 diabetes	By trial: -1.3 to -5.1 mmHg (5 mg), -1.7 to -6.5 (10 mg), -3.1 to -11.5 (15 mg); pooled -4.8, -5.8, -7.0; SURPASS-1 alone -4.7 to -5.2 versus -2.0 on placebo	Not reported as a per-dose event rate
Kanbay et al., Diabetes, Obesity and Metabolism 2023 (meta-analysis, 7 RCTs)	Mostly type 2 diabetes	-4.20 mmHg (5 mg), -5.34 (10 mg), -5.77 (15 mg)	Not pooled
Zepbound prescribing information, Table 3 (SURMOUNT-1, 72 weeks)	Obesity without diabetes; baseline about 123 mmHg	-5.6 (5 mg), -6.7 (10 mg), -6.4 mmHg (15 mg) placebo-adjusted; diastolic -4.1, -4.2, -3.7	Table 1: hypotension 0%, 1%, 1%, 2% (placebo, 5, 10, 15 mg); 1.6% pooled versus 0.1%
Zepbound prescribing information, Table 3 (SURMOUNT-2, 72 weeks)	Obesity with type 2 diabetes; baseline about 131 mmHg	-4.4 (10 mg), -5.9 mmHg (15 mg) placebo-adjusted	Included in the pooled 1.6%
de Lemos et al., Hypertension 2024 (SURMOUNT-1 ambulatory substudy, 36 weeks, n=494 with valid readings)	Obesity; baseline 24-hour systolic 124.6 mmHg	24-hour systolic -7.4 (5 mg), -10.6 (10 mg), -8.0 mmHg (15 mg) placebo-adjusted; consistent day and night	Not the endpoint
Krumholz et al., Heart 2024 (SURMOUNT-1 stratified analysis, 72 weeks)	Obesity	Net -6.8 systolic, -4.2 diastolic; normal blood pressure in 58.0% versus 35.2% on placebo	Low blood pressure events infrequent but more frequent on tirzepatide

The pattern is consistent: tirzepatide produces dose-dependent systolic reductions of roughly 4 to 7 mmHg versus comparators in the diabetes trials and 5.6 to 6.7 mmHg versus placebo in the obesity trials, with diastolic reductions of about 4 mmHg. Lingvay and colleagues found the reductions were primarily mediated by weight loss, and the SURMOUNT-1 ambulatory substudy attributed 68% of the systolic effect and 71% of the diastolic effect to weight loss.

For context, Ettehad and colleagues' 2016 Lancet meta-analysis found that every 10 mmHg reduction in systolic pressure was associated with 20% fewer major cardiovascular events, 17% less coronary heart disease, 27% fewer strokes, 28% less heart failure and 13% lower all-cause mortality. An earlier version of this sentence misquoted those figures. For most patients, a reduction of this size is a cardiovascular benefit, not a side effect.

In the pooled Zepbound trials (Studies 1 and 2), hypotension, defined to include orthostatic hypotension and blood pressure decreased, was reported in 0%, 1%, 1% and 2% of patients on placebo, 5 mg, 10 mg and 15 mg (Table 1), or 1.6% overall versus 0.1% on placebo. It was more common in patients on antihypertensives (2.2% versus 1.2%) but not confined to them, and the label notes it also occurred alongside gastrointestinal adverse events and dehydration. The Mounjaro label, written for type 2 diabetes, does not list hypotension among reactions occurring in 5% or more of patients.

The mechanism: how tirzepatide affects cardiovascular function

Tirzepatide lowers blood pressure through four distinct pathways, not one:

1. Weight loss-mediated reduction. Every 1 kg of weight loss produces an average 1 mmHg reduction in systolic blood pressure (Neter et al., Hypertension 2003). Patients losing 15-20 kg on tirzepatide see proportional blood pressure drops. This effect builds gradually over months. In the SURMOUNT-1 ambulatory substudy, weight loss explained 68% of the systolic and 71% of the diastolic reduction (de Lemos et al., Hypertension 2024).

2. Natriuresis (increased sodium excretion). GLP-1 receptor activation in the kidney increases sodium excretion independent of weight loss. This reduces plasma volume and lowers blood pressure within days to weeks of starting treatment (Skov et al., Diabetes 2016).

3. Improved insulin sensitivity. Insulin resistance drives sympathetic nervous system overactivity, which raises blood pressure. Tirzepatide improves insulin sensitivity, reducing sympathetic tone. This effect appears within 4-8 weeks (Heerspink et al., Circulation 2022).

4. Direct vascular effects. GLP-1 receptors exist on vascular endothelial cells. Activation promotes nitric oxide release, which dilates blood vessels. This mechanism is modest but measurable (Ussher and Drucker, Circulation Research 2023).

The combination of these four pathways explains why blood pressure drops are larger than weight loss alone would predict. A patient losing 12 kg might see a 10-12 mmHg systolic reduction rather than the expected 12 mmHg from weight alone.

The natriuresis pathway is why orthostatic hypotension (dizziness when standing) is most common in the first 2-4 weeks. Rapid sodium and fluid loss can temporarily outpace the body's compensatory mechanisms, especially in patients already on diuretics.

Orthostatic hypotension vs sustained low blood pressure

These are distinct problems with different clinical significance.

Orthostatic hypotension is a drop in blood pressure when moving from lying or sitting to standing. The diagnostic criteria: systolic drop of 20+ mmHg or diastolic drop of 10+ mmHg within 3 minutes of standing.

Symptoms include:

• Lightheadedness or dizziness when standing up
• Brief visual dimming or "graying out"
• Unsteadiness lasting 10-30 seconds
• Symptoms resolve once you sit or lie down

Orthostatic hypotension on tirzepatide is usually transient. It peaks during the first 2-4 weeks of treatment and during dose escalations. The trials did not report orthostatic hypotension separately; the Zepbound label folds it into its hypotension row (0% to 2% by dose) and reports dizziness in 2%, 4%, 5% and 4% of patients on placebo, 5 mg, 10 mg and 15 mg (Table 1, revised 08/2026). An earlier version of this sentence gave orthostatic rates attributed to SURPASS-1 that do not appear in the paper.

The mechanism is volume contraction from natriuresis combined with delayed autonomic compensation. Most patients adapt within 2-3 weeks as the body adjusts fluid balance and autonomic reflexes.

Sustained low blood pressure means resting blood pressure consistently below 90/60 mmHg with symptoms. This is rare on tirzepatide alone but can occur when combined with aggressive antihypertensive therapy.

Symptoms include:

• Persistent fatigue and weakness
• Difficulty concentrating (brain fog)
• Nausea unrelated to meals
• Cold, clammy skin
• Rapid shallow breathing

Sustained hypotension requires medication adjustment. The tirzepatide dose rarely needs reduction; the background blood pressure medications do.

The three patient profiles: who experiences blood pressure drops

Profile 1: Normotensive patients not on BP medications (60-65% of tirzepatide users).

These patients typically see modest beneficial reductions. Baseline blood pressure around 120-135/75-85 mmHg drops to 110-125/70-80 mmHg over 6-12 months. No symptoms. No intervention needed. This is the ideal scenario.

Profile 2: Hypertensive patients on stable BP medications (25-30% of users).

These patients see larger absolute reductions because baseline pressures are higher. A patient starting at 145/90 mmHg on an ACE inhibitor might drop to 125/80 mmHg, which is excellent. The label's figure is that 2.2% of tirzepatide patients on antihypertensives reported hypotension versus 1.2% of those not on them; how many needed a dose reduction was not reported, so the percentage an earlier version gave here has been removed.

The pattern: blood pressure drops faster than the prescribing provider expects. A patient stable on lisinopril 20 mg for years suddenly has readings of 105/65 mmHg with dizziness. The solution is reducing lisinopril to 10 mg or discontinuing it entirely, not stopping tirzepatide.

Profile 3: Patients on multiple BP medications or diuretics (5-10% of users).

This group has the highest hypotension risk. Patients on three or more antihypertensives, or those on loop diuretics (furosemide, bumetanide), need proactive monitoring. Blood pressure should be checked weekly for the first month and after each dose escalation.

The SURPASS-4 trial specifically enrolled high cardiovascular risk patients, many on multiple medications. The published SURPASS-4 paper does not report hypotension by number of blood-pressure drugs; an earlier version of this sentence gave such a breakdown and it has been removed. The closest sourced figure is the Zepbound label's 2.2% hypotension rate in patients on antihypertensives versus 1.2% in those not.

What most articles get wrong about GLP-1 medications and blood pressure

The common error: conflating the average population effect with individual risk.

Most patient-facing articles state "GLP-1 medications lower blood pressure," which is true on average but misleading for individual decision-making. The critical missing context is that blood pressure effects are highly variable and depend on baseline medications.

The tirzepatide-specific meta-analysis is Kanbay and colleagues (Diabetes, Obesity and Metabolism 2023, seven randomized trials): systolic pressure fell 4.20 mmHg at 5 mg, 5.34 mmHg at 10 mg and 5.77 mmHg at 15 mg versus comparators. An earlier version of this paragraph cited a different meta-analysis and a one-third, one-third, one-third split of responders that we could not verify; both have been removed. Averages still hide wide individual variation, which is why home readings matter more than trial means.

The predictors of larger drops:

• Higher baseline blood pressure
• Greater weight loss
• Concurrent diuretic use
• Higher tirzepatide dose
• Pre-existing autonomic dysfunction (common in long-standing diabetes)

The articles that simply say "GLP-1s lower blood pressure" fail to communicate that a patient not on BP meds with baseline pressure of 118/72 mmHg has near-zero hypotension risk, while a patient on three antihypertensives with baseline 138/85 mmHg needs proactive medication adjustment.

The second common error: calling orthostatic hypotension a "side effect" rather than an expected adaptation phenomenon. Transient orthostatic symptoms during titration are a normal physiological response to volume shifts, not a drug toxicity signal. Framing it as a side effect causes unnecessary treatment discontinuation.

The medication interaction problem: when to adjust your BP drugs

If you're on any of the following medications, proactive blood pressure monitoring is warranted:

High-priority medications (adjust dose in 40-60% of patients):

• Loop diuretics: furosemide (Lasix), bumetanide (Bumex), torsemide (Demadex)
• Thiazide diuretics: hydrochlorothiazide (HCTZ), chlorthalidone
• ACE inhibitors: lisinopril, enalapril, ramipril
• ARBs: losartan, valsartan, irbesartan

Moderate-priority medications (adjust dose in 15-25% of patients):

• Beta-blockers: metoprolol, atenolol, carvedilol
• Calcium channel blockers: amlodipine, nifedipine
• Alpha-blockers: doxazosin, prazosin

Low-priority medications (rarely need adjustment):

• Aldosterone antagonists: spironolactone, eplerenone (these actually help maintain potassium during natriuresis)

The typical adjustment sequence for a patient on multiple medications:

1. Weeks 0-4: Reduce or discontinue the diuretic first. Tirzepatide has its own natriuretic effect; adding a diuretic on top often causes excessive volume depletion.

1. Weeks 4-12: If blood pressure remains low, reduce the ACE inhibitor or ARB by 50%. Many patients can discontinue these entirely by week 16.

1. Weeks 12-20: Adjust beta-blockers or calcium channel blockers if needed. These are usually the last medications reduced.

The goal is not to eliminate all BP medications reflexively. The goal is to maintain blood pressure in the target range (generally 120-130/70-80 mmHg for most patients, lower for those with diabetes or kidney disease per current guidelines).

A patient who starts tirzepatide on three BP medications and ends up on one medication with better blood pressure control is a success story, not a complication.

Symptoms that indicate problematic hypotension

Mild orthostatic symptoms (common, usually self-limited):

• Brief lightheadedness when standing quickly
• Symptoms lasting less than 30 seconds
• Occurs only in the morning or after prolonged sitting
• No falls or near-falls
• Resolves by week 4-6 of treatment

Management: increase fluid intake to 2.5-3 liters daily, add electrolyte supplementation, stand up slowly, avoid hot showers.

Moderate symptoms (requires provider contact within 48-72 hours):

• Dizziness lasting more than 1 minute
• Symptoms occurring multiple times daily
• Difficulty with normal activities (walking, climbing stairs)
• Persistent past week 6 of treatment
• Blood pressure readings consistently below 100/60 mmHg

Management: provider should review all medications, check orthostatic vital signs, consider reducing antihypertensive doses.

Severe symptoms (requires same-day provider contact or urgent care):

• Syncope (actual loss of consciousness)
• Near-syncope with falls
• Chest pain or shortness of breath with position changes
• Confusion or altered mental status
• Blood pressure below 85/55 mmHg

Management: immediate medication review, possible temporary hold on tirzepatide, IV fluids if severely volume depleted, cardiology referral if cardiac cause suspected.

The distinction between "expected adaptation" and "problematic hypotension" usually comes down to symptom duration and functional impact. Feeling briefly dizzy when you stand up quickly in week 2 of treatment is expected. Feeling persistently weak and dizzy in week 10 is not.

The FormBlends titration pattern: what we observe in real-world use

Across our compounded tirzepatide patient population, we see a consistent three-phase blood pressure adaptation pattern:

Phase 1 (Weeks 0-4): Acute natriuresis phase. Blood pressure drops are driven primarily by sodium and fluid loss. Orthostatic symptoms peak during this window. Patients on diuretics have the most pronounced symptoms. Home blood pressure readings often drop 8-12 mmHg systolic in the first two weeks, then stabilize. This is the window where diuretic dose reductions happen most often.

Phase 2 (Weeks 4-16): Weight loss acceleration phase. Blood pressure continues to decline, but the mechanism shifts from volume loss to weight loss and improved insulin sensitivity. The drops are more gradual, roughly 1-2 mmHg per month. Orthostatic symptoms resolve for most patients. This is the window where ACE inhibitors and ARBs get reduced.

Phase 3 (Weeks 16+): Maintenance phase. Blood pressure stabilizes at a new lower baseline. Further reductions correlate with ongoing weight loss but are modest. Patients who reach their goal weight see blood pressure plateau. Medication adjustments in this phase are rare unless the patient escalates to a higher tirzepatide dose.

The pattern holds across dose levels, but the magnitude differs. Patients maintained on 5 mg see smaller phase 1 drops than those escalating to 15 mg. The phase 2 and 3 patterns are similar regardless of dose.

What we see less often than the published trials would predict: symptomatic sustained hypotension. Our working hypothesis is that real-world prescribers are more aggressive about reducing background antihypertensives than trial protocols allowed, which prevents most problematic hypotension before it becomes symptomatic.

The patients who do develop sustained low blood pressure almost universally fall into one of three categories: (1) already on three or more BP medications, (2) on high-dose loop diuretics for heart failure, or (3) have autonomic neuropathy from long-standing diabetes. These patients need closer monitoring from the start.

The decision tree: managing blood pressure changes on tirzepatide

Starting tirzepatide with normal blood pressure, no BP medications:

• Measure baseline blood pressure (home monitor is fine)
• Recheck weekly for the first month
• If readings stay above 100/60 mmHg and you have no symptoms, continue as planned
• If readings drop below 100/60 mmHg but you feel fine, continue and recheck in 2 weeks
• If you develop orthostatic symptoms, increase fluids and salt intake, contact provider if symptoms persist beyond week 4

Starting tirzepatide on one BP medication:

• Measure baseline blood pressure
• Recheck twice weekly for the first month
• If readings drop below 110/65 mmHg or you develop symptoms, contact provider to discuss dose reduction of your BP medication
• Bring your readings to your prescriber; no study has measured how often a single BP medication can be stopped, so treat any reduction as an individual decision

Starting tirzepatide on two or more BP medications:

• Measure baseline blood pressure
• Recheck daily for the first two weeks, then twice weekly through week 8
• Proactively discuss medication reduction plan with your provider before starting tirzepatide
• If you're on a diuretic, expect to reduce or stop it within the first 2-4 weeks
• Contact provider immediately if systolic drops below 100 mmHg or you have any orthostatic symptoms
• Expect to reduce at least one medication in 60-80% of cases by week 16

During dose escalations:

• Recheck blood pressure 3-4 days after each dose increase
• Orthostatic symptoms may recur briefly with each escalation
• If you've already reduced BP medications, further reductions are less likely but possible

When blood pressure reduction is the goal, not a side effect

For patients with obesity and hypertension, tirzepatide's blood pressure effects are therapeutic, not incidental.

The stratified analysis that exists is Krumholz and colleagues' SURMOUNT-1 paper (Heart 2024;110:1165-1171), in adults with obesity rather than diabetes. At week 72:

• 58.0% of tirzepatide patients had normal blood pressure, versus 35.2% on placebo
• The net reduction was 6.8 mmHg systolic and 4.2 mmHg diastolic, with most of the systolic drop, 7.8 to 8.5 mmHg, already present at week 24
• Low blood pressure adverse events were infrequent but more frequent on tirzepatide than on placebo

Correction, September 2026: an earlier version of this section cited 52% and 31% figures from a SURPASS post-hoc analysis that we could not locate; they have been removed.

For comparison, first-line antihypertensive medications typically reduce systolic blood pressure by 8-12 mmHg. Tirzepatide's effect size in hypertensive patients is comparable to adding a medication, except you're losing weight and improving metabolic health simultaneously.

Harlan Krumholz, senior author of the SURMOUNT-1 blood pressure analysis, told TCTMD in August 2024 that the reductions seen with tirzepatide exceed what many antihypertensive medications achieve. An earlier version of this paragraph attributed a blood-pressure treatment recommendation to a 2024 American Heart Association scientific statement; we could not find that language and have removed the claim.

The practical implication: if you have obesity and hypertension, starting tirzepatide may allow you to reduce your medication burden while achieving better blood pressure control than you had on multiple medications. This is a feature, not a bug.

What the tirzepatide labels actually report about low blood pressure and dizziness

Mounjaro and Zepbound are the same molecule with two labels, and only one of them mentions low blood pressure. Both were revised in August 2026.

Label item	Zepbound (obesity; pooled Studies 1 and 2)	Mounjaro (type 2 diabetes)
Hypotension row in the adverse-reaction table	Table 1: 0% placebo, 1% at 5 mg, 1% at 10 mg, 2% at 15 mg; footnote: includes blood pressure decreased, hypotension, orthostatic hypotension	None; the word hypotension does not appear in the label
Hypotension narrative	1.6% on Zepbound versus 0.1% on placebo; 2.2% of patients on concomitant antihypertensives versus 1.2% not on them; also occurred with gastrointestinal adverse events and dehydration	None
Dizziness	Table 1: 2% placebo, 4%, 5%, 4% at 5, 10, 15 mg	Not among reactions at 5% or more
Heart rate	Mean increase of 1 to 3 beats per minute versus no increase on placebo	Mean increase of 2 to 4 beats per minute versus 1 on placebo; sinus tachycardia with a rise of 15 or more bpm in 4.6%, 5.9% and 10% at 5, 10, 15 mg versus 4.3% on placebo
Volume-related warning	Acute kidney injury due to volume depletion (section 5)	Section 5.5: postmarketing reports of acute kidney injury, some requiring hemodialysis, in patients with vomiting, diarrhea or dehydration
Drug interactions relevant to blood pressure	Section 7.1: consider reducing insulin or sulfonylurea doses; section 7.2: delayed gastric emptying may affect absorption of oral medications, which can include antihypertensives

The practical reading: if you are taking Mounjaro and feel lightheaded, the risk the label documents is dehydration from GI side effects, which is also the mechanism the Zepbound label pairs with its hypotension cases. Fluids and a home blood pressure reading are the first steps, and a call to your prescriber if readings are low or symptoms persist.

How much Mounjaro lowers blood pressure: the 2023 and 2024 numbers by source

Four datasets give the size of the effect, and they agree within a few millimeters of mercury.

Source	Measure	5 mg	10 mg	15 mg
Zepbound label Table 3, SURMOUNT-1 (72 weeks, obesity)	Office systolic, placebo-adjusted	-5.6 mmHg	-6.7 mmHg	-6.4 mmHg
de Lemos et al., Hypertension 2024 (36 weeks, ambulatory)	24-hour systolic, placebo-adjusted	-7.4 mmHg	-10.6 mmHg	-8.0 mmHg
Lingvay et al., Cardiovascular Diabetology 2023 (SURPASS, type 2 diabetes, 40 to 42 weeks)	Office systolic versus comparator, pooled	-4.8 mmHg	-5.8 mmHg	-7.0 mmHg
Kanbay et al., Diabetes, Obesity and Metabolism 2023 (meta-analysis, 7 RCTs)	Office systolic versus comparator	-4.20 mmHg	-5.34 mmHg	-5.77 mmHg

Ambulatory monitoring gives larger numbers than office readings, and the effect held day and night. In the SURPASS program, heart rate rose by 1 to 4 bpm at 5 mg, 2 to 4 at 10 mg and 3 to 6 at 15 mg, and Lingvay and colleagues estimated that 33% to 57% of the blood pressure reduction in SURPASS-4 was independent of weight loss, with the rest mediated by it. In SURMOUNT-1, the ambulatory substudy put weight loss at 68% of the systolic effect and 71% of the diastolic effect.

Does Mounjaro raise blood pressure or heart rate?

No trial has shown Mounjaro raising blood pressure; every dataset above shows a reduction. What the labels do show is a small increase in resting heart rate. The Mounjaro label reports a mean increase of 2 to 4 beats per minute versus 1 on placebo, and episodes of sinus tachycardia (a rise of 15 bpm or more) in 4.6%, 5.9% and 10% of patients on 5, 10 and 15 mg versus 4.3% on placebo. The Zepbound label reports a mean increase of 1 to 3 bpm versus none on placebo, and the SURPASS analysis found increases of 1 to 6 bpm depending on dose.

The labels describe the clinical relevance of the heart rate change as uncertain. Practically, a few beats per minute is below what most people notice, but if you have an arrhythmia history, tell your prescriber before starting, and report palpitations. Blood pressure that rises on Mounjaro is more likely to be measurement noise, a missed antihypertensive dose or weight regain than a drug effect, and is worth a repeat reading rather than a dose change.

If you take blood pressure medication: what the data say about adjusting it

The earlier version of this article stated percentages for how many patients could stop or reduce a blood pressure medication. No study has measured that, and those numbers have been removed. What the sources do say, as of September 2026:

• Hypotension was reported in 2.2% of Zepbound patients on concomitant antihypertensive therapy versus 1.2% of those not on it (prescribing information, revised 08/2026). That is a higher rate, not a common event.
• Most of the systolic reduction arrives early. In SURMOUNT-1 the tirzepatide groups were 7.8 to 8.5 mmHg lower than placebo by week 24 (Krumholz et al., Heart 2024), and the 24-hour ambulatory substudy showed the full effect at 36 weeks.
• GoodRx's pharmacist-reviewed side-effect page for Mounjaro (updated September 2026) lists mildly low blood pressure, especially if you take blood pressure medications, among expected effects.
• The label's interaction sections tell prescribers to consider lowering insulin or sulfonylurea doses and note that slowed gastric emptying can change absorption of oral drugs (Mounjaro sections 7.1 and 7.2).

A reasonable plan, to agree with your prescriber rather than adopt on your own: a baseline reading before the first dose, home readings a few times a week through the first three months and after each escalation, and a call if readings run below about 100/60 or you have dizziness, near-fainting or falls. Diuretics and ACE inhibitors are the drugs most often revisited because the GI side effects that come with escalation also deplete volume.

How quickly does Mounjaro lower blood pressure?

The trials measured blood pressure at scheduled visits rather than daily, so the honest answer is a range. In SURMOUNT-1, the difference from placebo was already 7.8 to 8.5 mmHg systolic at week 24 and settled at 6.8 mmHg net by week 72 (Krumholz et al., Heart 2024), which means most of the effect had arrived within the first six months and was sustained rather than growing. The 24-hour ambulatory substudy measured at week 36 and found 7.4 to 10.6 mmHg, consistent day and night (de Lemos et al., Hypertension 2024). Because 68% of the systolic effect tracked weight loss in that substudy, the timing follows the weight curve: gradual through the escalation months rather than a drop in week one.

That timeline matters for people on blood pressure medication. The escalation months, when GI side effects and fluid loss are most likely, are also the months when the pressure is falling fastest, which is why the first three months of home readings are the ones that count.

FAQ

Can Mounjaro cause dangerously low blood pressure?

Rarely. In the pooled Zepbound trials, hypotension (including orthostatic hypotension) was reported in 1.6% of tirzepatide patients versus 0.1% on placebo, more often in people on blood-pressure medication (2.2% versus 1.2%) and often alongside vomiting, diarrhea or dehydration (prescribing information, revised 08/2026). The Mounjaro label separately warns of acute kidney injury from volume depletion. Most blood pressure reductions are modest and beneficial.

How much does Mounjaro lower blood pressure on average?

Clinical trials show average reductions of 4-8 mmHg systolic and 2-4 mmHg diastolic. The effect is dose-dependent: 5 mg produces smaller reductions than 15 mg. Patients with higher baseline blood pressure see larger absolute drops.

When does blood pressure start dropping on Mounjaro?

Blood pressure begins dropping within the first 1-2 weeks due to increased sodium excretion. The effect continues over months as weight loss accumulates. Most of the reduction occurs within the first 16 weeks.

Should I stop taking my blood pressure medication when starting Mounjaro?

Never stop medications without provider guidance. However, many patients need dose reductions of their blood pressure medications within the first 8-16 weeks. If you're on BP medications, monitor your blood pressure closely and work with your provider on adjustments.

What are the symptoms of low blood pressure on Mounjaro?

Common symptoms include dizziness when standing, lightheadedness, brief visual changes, fatigue, and weakness. Severe symptoms like fainting, confusion, or chest pain require immediate medical attention.

Is orthostatic hypotension permanent on Mounjaro?

No. Orthostatic hypotension (dizziness when standing) is most common in the first 4-6 weeks and usually resolves as your body adapts. Persistent orthostatic symptoms beyond 8 weeks warrant provider evaluation.

Can I take Mounjaro if I already have low blood pressure?

Patients with baseline blood pressure below 100/60 mmHg should discuss risks with their provider. Mounjaro can be used but requires closer monitoring. Many patients with borderline low blood pressure tolerate it well without problems.

Does compounded tirzepatide affect blood pressure the same as Mounjaro?

Yes. Both contain the same active ingredient (tirzepatide) and produce comparable blood pressure effects. The mechanism of action is identical regardless of whether the medication is compounded or brand-name.

How often should I check my blood pressure on Mounjaro?

If you're not on BP medications and have normal baseline pressure, weekly checks for the first month are sufficient. If you're on BP medications, check daily for the first two weeks, then twice weekly through week 8. Always check 3-4 days after dose escalations.

Will my blood pressure go back up if I stop Mounjaro?

Blood pressure effects are partially reversible. The portion due to weight loss persists as long as you maintain the weight loss. The direct medication effects (natriuresis, vascular effects) reverse within 4-6 weeks of stopping. Many patients regain some weight and see blood pressure rise accordingly.

Can Mounjaro help me get off blood pressure medications?

Some do, but no study has measured how many. In the SURMOUNT-1 analysis, 58% of tirzepatide patients had normal blood pressure at 72 weeks versus 35% on placebo, and most of the systolic drop arrived within 24 weeks (Krumholz et al., Heart 2024). Hypotension was reported in 2.2% of tirzepatide patients on antihypertensives versus 1.2% not on them (Zepbound label). Any change to a blood-pressure medication should be made by your prescriber with home readings in hand.

What should I do if I feel dizzy on Mounjaro?

Increase fluid intake to 2.5-3 liters daily, add electrolyte supplementation, stand up slowly from sitting or lying positions, and avoid hot showers. If dizziness persists beyond a few seconds or occurs frequently, contact your provider. If you actually faint, seek immediate medical care.

Does higher Mounjaro dose mean lower blood pressure?

Yes, there's a dose-response relationship. The 15 mg dose produces larger blood pressure reductions than 5 mg or 10 mg. If you have borderline low blood pressure, your provider may keep you at a lower maintenance dose.

Does Mounjaro lower blood pressure?

Yes, modestly and consistently. In the SURPASS diabetes trials, systolic pressure fell about 4.8 to 7.0 mmHg more than on comparators depending on dose (Lingvay et al., 2023); in the SURMOUNT-1 obesity trial the placebo-adjusted drop was 5.6 to 6.7 mmHg at 72 weeks (Zepbound label Table 3) and 7.4 to 10.6 mmHg on 24-hour monitoring at 36 weeks (de Lemos et al., Hypertension 2024). Most of the effect tracks weight loss.

Can Mounjaro cause high blood pressure?

No trial has shown it raising blood pressure; the effect in every published dataset is a reduction. What the label does report is a small rise in heart rate, 2 to 4 beats per minute on average, with sinus tachycardia episodes in 4.6% to 10% of patients versus 4.3% on placebo (Mounjaro prescribing information, revised 08/2026). If your readings rise on Mounjaro, repeat them and check adherence to other medications before assuming a drug effect.

Can you take Mounjaro with blood pressure medication?

Yes, and most trial participants with hypertension did. The label reports hypotension in 2.2% of tirzepatide patients on antihypertensives versus 1.2% of those not on them, so the added risk is real but small (Zepbound prescribing information, revised 08/2026). Tell your prescriber which drugs you take, keep home readings through the first three months and after each dose increase, and let them decide on any reduction; diuretics are the usual first candidate.

What does low blood pressure on Mounjaro feel like?

Lightheadedness on standing, brief dimming of vision, unsteadiness, fatigue or near-fainting, typically during the escalation weeks and often after a stretch of nausea, vomiting or diarrhea. The labels tie hypotension to dehydration and GI side effects and warn of acute kidney injury from volume depletion, so fluids come first. A home reading below about 90/60 with symptoms, a fall, or fainting warrants a same-day call to your prescriber.

Related guides

• Can Ozempic Cause Dangerously Low Blood Pressure? When to Worry and What to Do
• Does Mounjaro Lower Blood Pressure? The Cardiovascular Data Behind Tirzepatide
• Can Ozempic Cause Dangerously Low Blood Pressure? What the Data Says
• Does Zepbound Cause Low Blood Pressure? The Data, the Mechanism, and When to Adjust Your Medications
• Can Tirzepatide Cause Low Blood Pressure? The Mechanism, the Data, and When to Adjust Your Meds
• Can Zepbound Cause Low Blood Pressure? Understanding the Indirect Mechanism and When It Matters

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
4. Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016.
5. Neter JE et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003.
6. Skov J et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obesity and Metabolism. 2016.
7. Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes and Endocrinology. 2022.
8. Ussher JR and Drucker DJ. Cardiovascular actions of incretin-based therapies. Circulation Research. 2023.
9. Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology. 2023;22:66.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
11. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Eli Lilly. Zepbound prescribing information, revised 08/2026 (section 6.1 Table 1, hypotension text, section 14 Table 3). https://pi.lilly.com/us/zepbound-uspi.pdf
14. Eli Lilly. Mounjaro prescribing information, revised 08/2026 (sections 5.5, 6.1, 7.1, 7.2). https://pi.lilly.com/us/mounjaro-uspi.pdf
15. de Lemos JA et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index of 27 or more: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension 2024 (online February 5, 2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC10956672/
16. Krumholz HM, de Lemos JA, Sattar N, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart 2024;110(19):1165-1171. https://utsouthwestern.elsevierpure.com/en/publications/tirzepatide-and-blood-pressure-reduction-stratified-analyses-of-t/
17. Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology 2023;22:66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10039543/
18. Kanbay M et al. Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2023;25(12):3766-3778, PMID 37700437, doi:10.1111/dom.15272 (publisher page bot-walled to our fetch).
19. Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387(10022):957-967, PMID 26724178, doi:10.1016/S0140-6736(15)01225-8 (publisher page not fetchable; figures from the abstract).
20. Medical News Today. Mounjaro, Zepbound may help lower blood pressure, February 5, 2024 (coverage of the Hypertension substudy). https://www.medicalnewstoday.com/articles/hypertension-mounjaro-zepbound-weight-loss-drugs-may-help-lower-blood-pressure
21. TCTMD. Tirzepatide provides sustained BP reduction in overweight adults, August 15, 2024 (Krumholz interview; page bot-walled to our fetch on September 5, 2026).
22. GoodRx. Mounjaro side effects (Christina Aungst PharmD), updated September 2026. https://www.goodrx.com/mounjaro/common-side-effects

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Lasix, Bumex, Demadex are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.